share_log

乐普生物-B(02157.HK):三项临床研究成果在2024年ASCO年会上公布

Lepu Bio-B (02157.HK): Results of three clinical studies were announced at the 2024 ASCO Annual Meeting

Gelonghui Finance ·  May 23 18:35

On May 24, GLONGHUI (02157.HK) announced the results of three clinical studies of the company's innovative drug candidates and combination therapies (including antibody drug conjugates (“ADC”) MRG004A, MRG003 and HX008, and combination therapy with HX008 and Nirapali at the 2024 American Society of Clinical Oncology (“ASCO”) annual meeting.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment